Chronic Myeloid Leukaemia- Molecular Abnormalities and Treatment Options
Keywords:
medicineAbstract
Chronic myeloid leukaemia (CML) is a malignant, myeloproliferative disorder of haemopoietic
stem cells. It arises from a stem cell acquiring a specific translocation t(9;22) which results in
the formation of a hybrid oncogene, BCR-ABL. Selecting the most appropriate therapy for a
patient with CML remains difficult. Currently, stem cell transplantation is generally accepted
as offering the best prospect of a cure. However, advances in the study of tyrosine kinase
inhibitors and immunological treatments may direct the future of CML treatment.
References
Kantarjian HM. The biology of chronic myeloid
leukemia. N Engl J Med 1999;341:164-72.
2. Sawyers C. Chronic myeloid leukemia. N Engl J Med
1999; 340:1330-40.
3. Goldman JM. Chronic myeloid leukemia - advances
in biology and new approaches to treatment. N Engl J
Med 2003; 349:1452-64.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of
a selective inhibitor of the ABL tyrosine kinase on the
growth of BCR-ABL positive cells. Nat Med
1996;2:561-6.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and
safety of a specific inhibitor of the BCR-ABL tyrosine
kinase in chronic myeloid leukemia. N Engl J Med
2001;344:1031-7.
6. Kantarjian, H, Sawyers, C, Hochhaus, A, et al.
Hematologic and cytogenetic responses to imatinib
mesylate in chronic myelogenous leukemia. N Engl J
Med 2002;346:645-52.
7. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib
compared with interferon and low-dose cytarabine for
newly diagnosed chronic-phase chronic myeloid
leukemia. N Eng J Med 2003;348:994-1004.
8. Hughes TP, Kaeda J, Branford S, et al. Frequency of
major molecular responses to imatinib or interferon alfa
plus cytarabine in newly diagnosed chronic myeloid
leukemia. N Engl J Med 2003;349:1423-32.
9. Talpaz, M, Silver, RT, Druker, BJ, et al. Imatinib
induces durable hematologic and cytogenetic responses
in patients with accelerated phase chronic myeloid
leukemia: results of a phase 2 study. Blood
2002;99:1928-37.
10. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib
mesylate (STI571) therapy for Philadelphia
chromosome-positive chronic myelogenous leukemia
in blast phase. Blood 2002;99:3547-53.
11. British National Formulary 48, September 2004.
12. Guilhot F. Indications for imatinib mesylate therapy
and clinical management. Oncologist 2004;9:271-81.
13. Ren R. Mechanism of BCR-ABL in the
pathogenesis of chronic myelogenous leukaemia.
Nature Reviews Cancer 2005;5:172-82.
14. Gambacorti-Passerini CB, Gunby RH, Piazza R, et
al. Molecular mechanisms of resistance to imatinib in
Philadelphia-chromosome-positive leukaemias. Lancet
Oncol 2003;4:75.
15. Guilhot F, Chastang C, Michallet M, et al.
Interferon alfa-2b combined with cytarabine versus
interferon alone in chronic myelogenous leukemia. N
Engl J Med 1997;337(4):223-9.
16. Druker BJ, Sawyers CL, Capdeville R, Ford JM,
Baccarani M, Goldman JM. Chronic myelogenous
leukemia. Hematology 2001;2001:87-112.
17. Negrin R. Treatment of chronic myeloid leukemia.
(Accessed 11 March, 2005 at:
http://www.uptodate.com)
18. Negrin R. Hematopoietic cell transplantation in
chronic myeloid leukaemia. (Accessed 11 March, 2005
at: http://www.uptodate.com)
19. Goldman JM, Gale RP, Horowitz MM, et al. Bone
marrow transplantation for chronic myelogenous
leukemia in chronic phase: increased risk for relapse
associated with T-cell depletion. Ann Intern Med
1988;108:806-14.
20. Kolb HJ, Mittermüller J, Clemm C, et al. Donor
leukocyte transfusions for treatment of recurrent
chronic myelogenous leukemia in marrow transplant
patients. Blood 1990;76:2462-5.
21. Researchers at MD Anderson. Vaccination with the
PR1 Leukemia-Associated Antigen Can Induce
Complete Remission in Patients with Myeloid
Leukemia. 46th Annual Meeting of the American
Society of Hematology. Abstract 259.
22. Bocchia M, Gentili S, Abruzzese E, et al. Effect of
a p210 multipeptide vaccine associated with imatinib or
interferon in patients with chronic myeloid leukaemia
and persistent residual disease: a multicentre
observational trail. Lancet 2005;365:657-62.
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
